Colgate-Palmolive Earnings: Analysts Weigh In Ahead of Earnings Call

As Colgate-Palmolive (CL) prepares to release its fourth-quarter earnings before the opening bell on Friday, Jan. 31, analysts have been busy revising their forecasts and ratings. With the company's strong brand portfolio and growth initiatives, investors are eager to see how CL's earnings stack up against expectations. Let's dive into the most recent analyst opinions and see what they have to say about the upcoming earnings call.



Stifel analyst Mark Astrachan maintained a Hold rating but cut the price target from $101 to $95 on Jan. 17, 2025. Astrachan's accuracy rate of 75% suggests that his Hold rating may be a cautious but reasonable assessment of CL's near-term prospects. The reduction in the price target indicates a slight decrease in confidence, but the Hold rating suggests that Astrachan still sees the stock as a hold rather than a sell.

TD Cowen analyst Robert Moskow maintained a Buy rating but slashed the price target from $110 to $100 on Jan. 8, 2025. Moskow's accuracy rate of 67% indicates a moderate level of confidence in his Buy rating. The significant reduction in the price target, however, suggests that Moskow may be less confident in CL's short-term performance than he was previously.

Wells Fargo analyst Chris Carey maintained an Underweight rating and lowered the price target from $92 to $83 on Jan. 7, 2025. Carey's accuracy rate of 61% is the lowest among the analysts mentioned, which may indicate a higher level of caution in his Underweight rating. The reduction in the price target reflects Carey's decreased confidence in CL's stock performance.

Deutsche Bank analyst Steve Powers downgraded the stock from Buy to Hold but boosted the price target from $107 to $109 on Sept. 9, 2024. Powers' accuracy rate of 67% suggests a moderate level of confidence in his Hold rating. The downgrade from Buy to Hold indicates a decrease in confidence, but the slight increase in the price target suggests that Powers still sees some potential in the stock.

Morgan Stanley analyst Dara Mohsenian maintained an Overweight rating and increased the price target from $103 to $111 on July 29, 2024. Mohsenian's accuracy rate of 70% is the highest among the analysts mentioned, indicating a high level of confidence in her Overweight rating. The increase in the price target reflects Mohsenian's bullish outlook on CL's stock performance.



As we await Colgate-Palmolive's earnings call, investors can take comfort in the fact that the company has a strong brand portfolio and a history of delivering solid earnings growth. However, the divergent opinions of analysts highlight the uncertainty and varying levels of confidence in CL's near-term prospects. Investors should consider the accuracy rates and recent track records of these analysts when evaluating their recommendations.

In conclusion, while analysts' opinions vary regarding Colgate-Palmolive's stock, the company's strong brand portfolio and history of earnings growth suggest that it remains a solid investment option. As investors await the earnings call, they should stay informed about the company's performance and the latest analyst recommendations to make well-informed decisions.